BlackRock, Inc. ownership in CTSO / Cytosorbents Corporation

細胞吸附劑公司

US ˙ NasdaqCM ˙ US23283X2062

Security	CTSO / Cytosorbents Corporation
Institution	BlackRock, Inc.
Latest Disclosed Ownership	744,958 shares
Ownership	1.70%

2022-07-08 - BlackRock, Inc. has filed an SC 13G form with the Securities and Exchange Commission (SEC) disclosing ownership of 744,958 shares of Cytosorbents Corporation (US:CTSO). This represents 1.7 percent ownership of the company. In their previous filing dated 2022-02-03 , BlackRock, Inc. had reported owning 2,631,210 shares, indicating a decrease of -71.69 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File Date	Effective Date	Form	Prev Shares	Latest Shares	ΔShares (Percent)	Ownership (Percent)	ΔOwnership (Percent)
2022-07-08	2022-07-08	13G	2,631,210	744,958	-71.69	1.70	-72.13
2022-02-03	2022-02-03	13G/A	2,762,288	2,631,210	-4.75	6.10	-4.69
2021-01-29	2021-01-29	13G/A	2,059,602	2,762,288	34.12	6.40	0.00
2020-02-05	2020-02-05	13G/A	1,985,640	2,059,602	3.72	6.40	1.59
2019-02-08	2019-02-08	13G	1,985,640	1,985,640	0.00	6.30	0.00
2019-02-07	2019-02-07	13G		1,985,640		6.30

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel Premium Registration Required .

Disclosed Equity Positions (from 13F/NPORT Filings)

File Date	Effective Date	Form	Security	Class	ID	Reported Shares	ΔShares	ΔShares (%)	Reported Value (x1000)	ΔValue (%)	Alloc (%)
2026-05-13	2026-03-31	13F	CYTOSORBENTS	COM NEW	23283X206	782,992	12,441	1.61	443	-9.96	0.0000
2026-02-12	2025-12-31	13F	CYTOSORBENTS	COM NEW	23283X206	770,551	5,742	0.75	493	-31.09	0.0000
2025-11-12	2025-09-30	13F	CYTOSORBENTS	COM NEW	23283X206	764,809	19,196	2.57	714	-25.16	0.0000
2025-08-12	2025-06-30	13F	CYTOSORBENTS	COM NEW	23283X206	745,613	118,308	18.86	954	52.15	0.0000
2025-05-02	2025-03-31	13F	CYTOSORBENTS	COM NEW	23283X206	627,305	0	0.00	627	10.00	0.0000
2025-02-07	2024-12-31	13F	CYTOSORBENTS	COM NEW	23283X206	627,305	0	0.00	571	-39.36	0.0000
2024-11-13	2024-09-30	13F	CYTOSORBENTS	COM NEW	23283X206	627,305	-28,500	-4.35	941	103.90	0.0000
2024-08-13	2024-06-30	13F	CYTOSORBENTS	COM NEW	23283X206	655,805	-66,630	-9.22	461	-32.80	0.0000
2024-05-10	2024-03-31	13F	CYTOSORBENTS	COM NEW	23283X206	722,435	-3,885	-0.53	686	-14.89	0.0000
2024-02-13	2023-12-31	13F	CYTOSORBENTS	COM NEW	23283X206	726,320	-444	-0.06	806	-41.00	0.0000
2023-11-13	2023-09-30	13F	CYTOSORBENTS	COM NEW	23283X206	726,764	-33,247	-4.37	1,366	-49.93	0.0000
2023-08-11	2023-06-30	13F	CYTOSORBENTS	COM NEW	23283X206	760,011	15,107	2.03	2,728	8.69	0.0001
2023-05-12	2023-03-31	13F	CYTOSORBENTS	COM NEW	23283X206	744,904	2,847	0.38	2,510	118.26	0.0001
2023-02-13	2022-12-31	13F	CYTOSORBENTS	COM NEW	23283X206	742,057	686	0.09	1,150	13.97	0.0000
2022-11-14	2022-09-30	13F	CYTOSORBENTS	COM NEW	23283X206	741,371	-3,587	-0.48	1,009	-38.17	0.0000
2022-08-12	2022-06-30	13F	CYTOSORBENTS	COM NEW	23283X206	744,958	-1,855,479	-71.35	1,632	-80.33	0.0001
2022-05-12	2022-03-31	13F	CYTOSORBENTS	COM NEW	23283X206	2,600,437	-30,773	-1.17	8,295	-24.76	0.0002
2022-02-10	2021-12-31	13F	CYTOSORBENTS	COM NEW	23283X206	2,631,210	72,418	2.83	11,024	-46.94	0.0003
2021-11-09	2021-09-30	13F	CYTOSORBENTS	COM NEW	23283X206	2,558,792	-82,374	-3.12	20,777	4.19	0.0006
2021-08-11	2021-06-30	13F	CYTOSORBENTS	COM NEW	23283X206	2,641,166	-187,436	-6.63	19,941	-18.78	0.0006
2021-05-07	2021-03-31	13F	CYTOSORBENTS	COM NEW	23283X206	2,828,602	66,314	2.40	24,552	11.52	0.0007
2021-02-05	2020-12-31	13F	CYTOSORBENTS	COM NEW	23283X206	2,762,288	68,756	2.55	22,016	2.49	0.0007
2020-11-06	2020-09-30	13F	CYTOSORBENTS	COM NEW	23283X206	2,693,532	407,749	17.84	21,481	-5.08	0.0008
2020-08-14	2020-06-30	13F	CYTOSORBENTS	COM NEW	23283X206	2,285,783	189,135	9.02	22,630	39.63	0.0009
2020-05-01	2020-03-31	13F	CYTOSORBENTS	COM NEW	23283X206	2,096,648	37,046	1.80	16,207	104.38	0.0008
2020-02-13	2019-12-31	13F	CYTOSORBENTS	COM NEW	23283X206	2,059,602	-577	-0.03	7,930	-23.48	0.0003
2019-11-08	2019-09-30	13F	CYTOSORBENTS	COM NEW	23283X206	2,060,179	52,056	2.59	10,363	-21.93	0.0004
2019-08-22	2019-06-30	13F/A-1	CYTOSORBENTS	COM NEW	23283X206	2,008,123	21,791	1.10	13,274	-11.72	0.0006
2019-08-13	2019-06-30	13F	CYTOSORBENTS	COM NEW	23283X206	2,008,123	21,791		13,274
2019-05-09	2019-03-31	13F	CYTOSORBENTS	COM NEW	23283X206	1,986,332	692	0.03	15,037	-6.29	0.0007
2019-02-08	2018-12-31	13F	CYTOSORBENTS	COM NEW	23283X206	1,985,640	23,891	1.22	16,046	-36.60	0.0008
2018-11-09	2018-09-30	13F	CYTOSORBENTS	COM NEW	23283X206	1,961,749	254,902	14.93	25,308	30.06	0.0011
2018-08-09	2018-06-30	13F	CYTOSORBENTS	COM NEW	23283X206	1,706,847	1,571,041	1,156.83	19,459	1,931.21	0.0009
2018-05-09	2018-03-31	13F	CYTOSORBENTS	COM NEW	23283X206	135,806	-4,331	-3.09	958	5.16	0.0000
2018-02-09	2017-12-31	13F	CYTOSORBENTS	COM NEW	23283X206	140,137	3,320	2.43	911	7.43	0.0000
2017-11-14	2017-09-30	13F	CYTOSORBENTS	COM NEW	23283X206	136,817	24,643	21.97	848	75.57	0.0000
2017-08-10	2017-06-30	13F	CYTOSORBENTS	COM NEW	23283X206	112,174	-6,999	-5.87	483	-9.89	0.0000
2017-05-12	2017-03-31	13F	CYTOSORBENTS	COM NEW	23283X206	119,173	118,773	29,693.25	536	26,700.00	0.0000
2017-02-10	2016-12-31	13F	CYTOSORBENTS	COM NEW	23283X206	400	0	0.00	2	-33.33	0.0000
2016-11-08	2016-09-30	13F	CYTOSORBENTS	COM NEW	23283X206	400	400		3		0.0000

Legend

Shares: The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value: The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price: The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class: This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred

Allocation (%): The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation: The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%): The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis: The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss: This is the market value of the position as of the effective date minus the cost basis.